Answers are grounded in this paper and cite their sources.
Real-world data suggest that lurbinectedin is a viable option for patients with SCLC who have progressed on or after platinum-based chemotherapy.
No takes yet. Share an insight, caveat, or question.
Shim et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: